Clinical trial · no report yet · Phase 3
NCT06448312
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT06448312 ↗
- Active not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for PD-L1 Positive Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SKB264; Pembrolizumab
- Arms
- SKB264+Pembrolizumab · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 406 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Jun 7, 2024
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06448312 · updated May 8, 2026
Publications
linked from the registry- Xiong A, Yao W, Zheng W, Yu Y, Chen P, Zhong H, Ge J, Wang H, Chen B, Wang H, Fan Y, Yang Y, Pu X, Song X, Wang Q, Du X, Huang Z, Li X, Luo H, Yao Y, Yu Q, Su C, He L, Jiang G, Cui J, Liu C, Yi T, Che G, Liu Z, Zhang L, Zhou M, Fang Y, Wei Y, Qing Y, Jin X, Zhou C. Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet. 2026 Jun 27;407(10548):2607-2619. doi: 10.1016/S0140-6736(26)00968-2. Epub 2026 May 29. PubMed 42214392